Author: Condie Carmack

Suffering is what makes it special

Published on November 5, 2025 8:04 AM GMT It’s weird living in an approximately post-scarcity part of the world. Competitions aren’t much about survival, they’re sometimes about comfort and always about status. Houses are essentially free, if you’re willing to live where there’s less competition and no jobs. Soon the AI will automate the remaining […]

$NVO Last opportunity!

$NVO Last opportunity! Novo Nordisk A/S Sponsored ADR Class B BATS:NVO alexei_erchov 🌱 Novo Nordisk: A Healthy Pullback in a Long-Term Growth Story After years of remarkable growth, Novo Nordisk (NYSE: NVO) has seen its stock cool off — sliding from over 💲130 to around 💲49. At first glance, that might look alarming, but the […]

Britain’s plan to raise NHS drug prices won’t bring back Lilly’s investment

LONDON — The American drugmaker Eli Lilly wants to see more changes to Britain’s medicine market before it pivots on its abandoned £279 million investment in a biotech incubator project. The U.K. government has drawn up proposals to increase the amount the state-funded National Health Service is allowed to pay pharmaceutical firms for drugs after intense discussions […]

GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis

Abstract Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with significant cardiovascular (CV) benefits in patients with type 2 diabetes mellitus (DM). However, the efficacy and safety among different agents across diverse patient populations remain inadequately defined. Purpose We conducted a systematic review, along with pairwise and network meta-analysis, to assess the safety and […]

Do GLP-1 drugs cause cancer? New review says no, may even protect

A comprehensive review in The Journal of Clinical Investigation finds no overall link between GLP-1 receptor agonists and increased cancer risk, countering early safety concerns. Instead, evidence suggests possible protective effects for certain cancers, supported by metabolic and immune-modulating mechanisms.

Trump’s MRI remains a mystery

Presented by the Coalition to Strengthen America’s Healthcare {beacon} Health Care PRESENTED BY COALITION TO STRENGTHEN AMERICA’S HEALTHCARE The Big Story  Trump’s MRI remains a mystery  A week after President Trump’s off-the-cuff remark that he had an MRI scan performed, we still don’t know why. And it will likely stay that way.  © Photo credit Trump’s disclosure raised fresh questions about the secrecy surrounding […]

Metsera in the middle of Novo, Pfizer bidding war

Pfizer Inc. upped its original $7.3 billion September offer to buy Metsera Inc., but the obesity specialist maintained that a now-improved unsolicited bid by semaglutide developer Novo Nordisk A/S is superior.

Is there really an Ozempic baby boom?

These medications may be influencing fertility in ways scientists are only beginning to understand. When the GLP-1 medications were first approved for weight loss, “I got pregnant on Ozempic” headlines quickly followed. People spoke about sudden unintended pregnancy, and “Ozempic babies” entered the lexicon. Could a medication meant to combat diabetes and shrink waistlines also […]

GLP-1 drugs calm inflammation beyond diabetes and weight loss

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent mechanisms. It details preclinical and clinical evidence linking GLP-1 receptor activation to cardiovascular, renal, hepatic, neural, and joint anti-inflammatory effects while outlining uncertainties and future research needs.